Eagle Asset Management Inc. grew its position in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 34.7% in the second quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 317,650 shares of the company’s stock after buying an additional 81,790 shares during the quarter. Eagle Asset Management Inc. owned 0.36% of IDEXX Laboratories worth $51,275,000 as of its most recent filing with the SEC.
Other institutional investors have also recently made changes to their positions in the company. 1st Global Advisors Inc. raised its position in IDEXX Laboratories by 1.2% during the 1st quarter. 1st Global Advisors Inc. now owns 7,548 shares of the company’s stock worth $1,167,000 after buying an additional 88 shares during the last quarter. Sei Investments Co. raised its position in IDEXX Laboratories by 76.6% during the 1st quarter. Sei Investments Co. now owns 20,277 shares of the company’s stock worth $3,135,000 after buying an additional 8,792 shares during the last quarter. AXA raised its position in IDEXX Laboratories by 52.0% during the 1st quarter. AXA now owns 346,593 shares of the company’s stock worth $53,587,000 after buying an additional 118,643 shares during the last quarter. Pitcairn Co. raised its position in IDEXX Laboratories by 21.8% during the 2nd quarter. Pitcairn Co. now owns 6,977 shares of the company’s stock worth $1,126,000 after buying an additional 1,249 shares during the last quarter. Finally, Cutler Group LP raised its position in IDEXX Laboratories by 65.2% during the 2nd quarter. Cutler Group LP now owns 3,800 shares of the company’s stock worth $613,000 after buying an additional 1,500 shares during the last quarter. Institutional investors own 87.73% of the company’s stock.
Shares of IDEXX Laboratories, Inc. (IDXX) traded up 0.11% during midday trading on Friday, reaching $158.97. 774,056 shares of the company were exchanged. The company has a market capitalization of $13.87 billion, a PE ratio of 54.69 and a beta of 0.49. IDEXX Laboratories, Inc. has a 52-week low of $102.45 and a 52-week high of $173.01. The firm’s 50 day moving average is $155.18 and its 200-day moving average is $158.87.
IDEXX Laboratories (NASDAQ:IDXX) last issued its quarterly earnings results on Tuesday, August 1st. The company reported $0.95 EPS for the quarter, topping the consensus estimate of $0.85 by $0.10. IDEXX Laboratories had a net margin of 14.13% and a negative return on equity of 473.46%. The firm had revenue of $508.90 million for the quarter, compared to analysts’ expectations of $502.44 million. During the same period in the previous year, the business earned $0.74 earnings per share. IDEXX Laboratories’s revenue for the quarter was up 9.1% compared to the same quarter last year. On average, equities analysts forecast that IDEXX Laboratories, Inc. will post $3.18 earnings per share for the current fiscal year.
In other IDEXX Laboratories news, Chairman Jonathan W. Ayers sold 17,000 shares of the business’s stock in a transaction dated Wednesday, August 9th. The shares were sold at an average price of $154.54, for a total value of $2,627,180.00. Following the sale, the chairman now directly owns 1,039,034 shares in the company, valued at $160,572,314.36. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Chairman Jonathan W. Ayers sold 13,000 shares of the business’s stock in a transaction dated Monday, August 28th. The stock was sold at an average price of $150.79, for a total transaction of $1,960,270.00. Following the completion of the sale, the chairman now owns 1,044,034 shares in the company, valued at $157,429,886.86. The disclosure for this sale can be found here. Over the last quarter, insiders sold 151,734 shares of company stock worth $23,436,626. 2.77% of the stock is owned by company insiders.
COPYRIGHT VIOLATION NOTICE: “IDEXX Laboratories, Inc. (IDXX) Holdings Increased by Eagle Asset Management Inc.” was published by The Ledger Gazette and is the property of of The Ledger Gazette. If you are accessing this report on another domain, it was copied illegally and republished in violation of U.S. & international trademark & copyright laws. The correct version of this report can be read at https://ledgergazette.com/2017/09/17/eagle-asset-management-inc-increases-position-in-idexx-laboratories-inc-idxx.html.
A number of equities analysts have commented on the stock. Zacks Investment Research upgraded shares of IDEXX Laboratories from a “hold” rating to a “buy” rating and set a $187.00 price objective for the company in a research report on Monday, May 29th. Canaccord Genuity reiterated a “buy” rating and issued a $180.00 price target on shares of IDEXX Laboratories in a report on Tuesday, June 13th. Aegis assumed coverage on shares of IDEXX Laboratories in a report on Wednesday, May 31st. They issued a “sell” rating and a $118.00 price target for the company. They noted that the move was a valuation call. BidaskClub upgraded shares of IDEXX Laboratories from a “buy” rating to a “strong-buy” rating in a report on Friday, June 23rd. Finally, CL King upgraded shares of IDEXX Laboratories from a “neutral” rating to a “buy” rating and set a $200.00 price target for the company in a report on Friday, July 28th. Two equities research analysts have rated the stock with a sell rating, one has issued a hold rating and five have assigned a buy rating to the company. The company has a consensus rating of “Hold” and an average price target of $174.00.
IDEXX Laboratories Company Profile
IDEXX Laboratories, Inc develops, manufactures and distributes products and provides services for the companion animal veterinary, livestock and poultry, dairy and water testing markets. The Company also sells a line of portable electrolytes and blood gas analyzers for the human point-of-care medical diagnostics market.
Receive News & Ratings for IDEXX Laboratories Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEXX Laboratories Inc. and related companies with MarketBeat.com's FREE daily email newsletter.